190 related articles for article (PubMed ID: 37133642)
1. Denosumab for osteoporosis in patients with primary hyperparathyroidism and mild-to-moderate renal insufficiency.
Gronskaya S; Belaya Z; Rozhinskaya L; Mamedova E; Vorontsova M; Solodovnikov A; Golounina O; Melnichenko G
Endocrine; 2023 Aug; 81(2):368-378. PubMed ID: 37133642
[TBL] [Abstract][Full Text] [Related]
2. Protective Effect of Denosumab on Bone in Older Women with Primary Hyperparathyroidism.
Eller-Vainicher C; Palmieri S; Cairoli E; Goggi G; Scillitani A; Arosio M; Falchetti A; Chiodini I
J Am Geriatr Soc; 2018 Mar; 66(3):518-524. PubMed ID: 29364518
[TBL] [Abstract][Full Text] [Related]
3. Denosumab Safety and Efficacy Among Participants in the FREEDOM Extension Study With Mild to Moderate Chronic Kidney Disease.
Broadwell A; Chines A; Ebeling PR; Franek E; Huang S; Smith S; Kendler D; Messina O; Miller PD
J Clin Endocrinol Metab; 2021 Jan; 106(2):397-409. PubMed ID: 33211870
[TBL] [Abstract][Full Text] [Related]
4. Impaired residual renal function predicts denosumab-induced serum calcium decrement as well as increment of bone mineral density in non-severe renal insufficiency.
Miyaoka D; Imanishi Y; Ohara M; Hayashi N; Nagata Y; Yamada S; Mori K; Emoto M; Inaba M
Osteoporos Int; 2019 Jan; 30(1):241-249. PubMed ID: 30187112
[TBL] [Abstract][Full Text] [Related]
5. Pharmacological interventions versus placebo, no treatment or usual care for osteoporosis in people with chronic kidney disease stages 3-5D.
Hara T; Hijikata Y; Matsubara Y; Watanabe N
Cochrane Database Syst Rev; 2021 Jul; 7(7):CD013424. PubMed ID: 34231877
[TBL] [Abstract][Full Text] [Related]
6. Efficacy and safety of denosumab treatment for Korean patients with Stage 3b-4 chronic kidney disease and osteoporosis.
Kim JT; Kim YM; Jung KY; Choi H; Lee SY; Kim HJ
Korean J Intern Med; 2024 Jan; 39(1):148-159. PubMed ID: 38145616
[TBL] [Abstract][Full Text] [Related]
7. Osteoporosis, bone mineral density and CKD-MBD: treatment considerations.
Bover J; Bailone L; López-Báez V; Benito S; Ciceri P; Galassi A; Cozzolino M
J Nephrol; 2017 Oct; 30(5):677-687. PubMed ID: 28432640
[TBL] [Abstract][Full Text] [Related]
8. Teriparatide in postmenopausal women with osteoporosis and mild or moderate renal impairment.
Miller PD; Schwartz EN; Chen P; Misurski DA; Krege JH
Osteoporos Int; 2007 Jan; 18(1):59-68. PubMed ID: 17013567
[TBL] [Abstract][Full Text] [Related]
9. Hypocalcemia post denosumab in patients with chronic kidney disease stage 4-5.
Dave V; Chiang CY; Booth J; Mount PF
Am J Nephrol; 2015; 41(2):129-37. PubMed ID: 25790847
[TBL] [Abstract][Full Text] [Related]
10. Efficacy and Safety of Romosozumab Among Postmenopausal Women With Osteoporosis and Mild-to-Moderate Chronic Kidney Disease.
Miller PD; Adachi JD; Albergaria BH; Cheung AM; Chines AA; Gielen E; Langdahl BL; Miyauchi A; Oates M; Reid IR; Santiago NR; Vanderkelen M; Wang Z; Yu Z
J Bone Miner Res; 2022 Aug; 37(8):1437-1445. PubMed ID: 35466448
[TBL] [Abstract][Full Text] [Related]
11. Baseline Characteristics and Changes in Bone Mineral Density T-Scores of Bulgarian Women with Postmenopausal Osteoporosis Receiving Denosumab in Routine Clinical Practice.
Boyanov M; Shinkov A; Psachoulia E; Intorcia M; Petkova R
Drugs R D; 2017 Mar; 17(1):125-132. PubMed ID: 27988913
[TBL] [Abstract][Full Text] [Related]
12. 10 years of denosumab treatment in postmenopausal women with osteoporosis: results from the phase 3 randomised FREEDOM trial and open-label extension.
Bone HG; Wagman RB; Brandi ML; Brown JP; Chapurlat R; Cummings SR; Czerwiński E; Fahrleitner-Pammer A; Kendler DL; Lippuner K; Reginster JY; Roux C; Malouf J; Bradley MN; Daizadeh NS; Wang A; Dakin P; Pannacciulli N; Dempster DW; Papapoulos S
Lancet Diabetes Endocrinol; 2017 Jul; 5(7):513-523. PubMed ID: 28546097
[TBL] [Abstract][Full Text] [Related]
13. Effects of denosumab as compared with parathyroidectomy regarding calcium, renal, and bone involvement in osteoporotic patients with primary hyperparathyroidism.
Miyaoka D; Imanishi Y; Kato E; Toi N; Nagata Y; Kurajoh M; Yamada S; Inaba M; Emoto M
Endocrine; 2020 Sep; 69(3):642-649. PubMed ID: 32621048
[TBL] [Abstract][Full Text] [Related]
14. Efficacy and safety of romosozumab among Japanese postmenopausal women with osteoporosis and mild-to-moderate chronic kidney disease.
Miyauchi A; Hamaya E; Nishi K; Tolman C; Shimauchi J
J Bone Miner Metab; 2022 Jul; 40(4):677-687. PubMed ID: 35639174
[TBL] [Abstract][Full Text] [Related]
15. The effect of previous treatment with bisphosphonate and renal impairment on the response to denosumab in osteoporosis: a 'real-life' study.
Fraser TR; Flogaitis I; Moore AE; Hampson G
J Endocrinol Invest; 2020 Apr; 43(4):469-475. PubMed ID: 31664706
[TBL] [Abstract][Full Text] [Related]
16. Clinical effects of switching from minodronate to denosumab treatment in patients with postmenopausal osteoporosis: a retrospective study.
Kobayashi M; Sawada K; Yoshimura A; Yamamoto M; Shimizu A; Shimura K; Komura N; Miyamoto M; Ishida K; Kimura T
BMC Womens Health; 2020 Mar; 20(1):48. PubMed ID: 32138724
[TBL] [Abstract][Full Text] [Related]
17. [Experience in using Prolia in patients with postmenopausal osteoporosis in clinical practice].
Skripnikova IA; Kosmatova OV; Abirova ES; Novikov VE; Murashko LM
Ter Arkh; 2017; 89(12. Vyp. 2):190-196. PubMed ID: 29488480
[TBL] [Abstract][Full Text] [Related]
18. Individual site-specific bone mineral density gain in normocalcemic primary hyperparathyroidism.
Koumakis E; Souberbielle JC; Payet J; Sarfati E; Borderie D; Kahan A; Cormier C
Osteoporos Int; 2014 Jul; 25(7):1963-8. PubMed ID: 24676846
[TBL] [Abstract][Full Text] [Related]
19. Benefits and Harms of Osteoporosis Medications in Patients With Chronic Kidney Disease: A Systematic Review and Meta-analysis.
Wilson LM; Rebholz CM; Jirru E; Liu MC; Zhang A; Gayleard J; Chu Y; Robinson KA
Ann Intern Med; 2017 May; 166(9):649-658. PubMed ID: 28395318
[TBL] [Abstract][Full Text] [Related]
20. Young patients and those with a low eGFR benefitted more from denosumab therapy in femoral neck bone mineral density.
Cheng BC; Chen YC
Clin Rheumatol; 2017 Apr; 36(4):929-932. PubMed ID: 27757701
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
